SK Biopharmaceuticals remains in red in Q3

BRAND / 영문경제 / 2022-11-10 09:10:14
  • facebook
  • twitter
  • kakao
  • naver
  • band
SK Biopharmaceuticals-Q3 earnings

SK Biopharmaceuticals-Q3 earnings

SK Biopharmaceuticals remains in red in Q3

SEOUL, Nov. 10 (Yonhap) -- SK Biopharmaceuticals Co. on Thursday reported its third-quarter net loss of 15 billion won (US$10.9 million), remaining in the red compared with a year ago.

The company said in a regulatory filing that it continued to post an operating loss of 9.2 billion won for the July-September period, compared with a loss of 49.9 billion won a year earlier. Sales rose 270.9 percent to 88.8 billion won.

The operating loss was 38.3 percent lower than the average estimate, according to a survey by Yonhap Infomax, the financial data firm of Yonhap News Agency.

(END)

(C) Yonhap News Agency. All Rights Reserved

  • facebook
  • twitter
  • kakao
  • pinterest
  • naver
  • band